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Abstract
Introduction Acromegaly is a rare disorder in which, due
to the high incidence of secondary hypogonadism, preg-
nancies are relatively rare. However, some women with
acromegaly do get pregnant, which brings along questions
about medication, complications and follow-up. This
review tries to address these issues and provide the reader
with practical information.
Methods This review summarizes published data.
Conclusions Acromegaly is a disorder that is characterized
by changes in growth hormone (GH), insulin-like growth
factor-1 (IGF-1) and insulin concentrations and actions. All
these hormones are important in pregnancy as well. In
principle, the fetal-placental collaboration between mother
and child more-or-less takes over the control over GH and
IGF-1, not only in normal physiology but also to a certain
extend in acromegaly. When medication for the high GH
levels or actions is continued during pregnancy, both
dopamine agonists, somatostatin analogs and GH receptor
antagonists have been used and the available data suggest
that there are no adverse consequences on mother or fetus
to date. However, it is strongly advised to stop any medical
intervention during pregnancy until more data are available
on the safety of these compounds. Also, medical treatment
is not needed as tumor size and disease activity are not
reported to escape.
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Introduction
Acromegaly is a rare syndrome that results when the
anterior pituitary gland produces excess growth hormone
(GH) after epiphyseal plate closure at puberty. The dis-
order is further characterized by changes in insulin-like
growth factor-1 (IGF-1) and insulin concentrations and
actions. During pregnancy, these hormones are important
in pregnancy as well. Also other processes, as methyla-
tion play an important role in the fetal-placental interplay
[1].
In normal pregnancy, the physiological increase in
estrogen and progesterone decrease the sensitivity of the
liver [2]. During the second half of normal pregnancy,
the human placenta secretes placental GH in increasing
amounts up to delivery while at the same time, pituitary
GH secretion is progressively suppressed [3]. These two
changes are probably the main reasons behind the
apparent lack of biochemical escape in pregnant acro-
megaly patients when medical treatment is stopped [4].
Therefore, it is commonly not necessary to continue
medical treatment for active acromegaly during pregnan-
cies. In this review, we try to address the (patho)physio-
logical metabolic background of normal pregnancy versus
pregnancy in acromegaly patients. Also we discuss the
available safety data of medical treatment modalities for
acromegaly.
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What is different and what is identical
in the hormonal patterns between normal
pregnancies and the ones in acromegaly
In a nice overview by Verhaeghe [5], it is explained in
detail that normal pregnancies are accompanied by
notable changes in the secretion of GH and IGFs. Placental
GH (pGH) is discernible in maternal plasma from early
pregnancy, rising exponentially until 37 weeks. Mean-
while, pituitary GH gradually drops to near-unde-
tectable levels. While there might be a modest reduction in
circulating IGF-I in early pregnancy, IGF-I increases two-
to three-fold in the second half, again with a peak at around
37 weeks. Thus, placental GH is believed to replace pitu-
itary GH as the primary stimulus for IGF-I secretion in
pregnancy [5]. IGF-II concentrations also appear to show a
modest (20–25 %) increase in the course of pregnancy [5].
All-in-all, during normal pregnancy a ‘gestational acro-
megaly’ develops in order to foster fetoplacental growth.
Placental and maternal pituitary hormones tightly regu-
late fetal growth and placental GH mobilizes maternal
nutrients for fetal growth by inducing maternal insulin
resistance [6]. However, the adenomatous tumor cells
appear to be resistant to the factors that usually inhibit
pituitary GH secretion during the second part of normal
pregnancy. In acromegaly, the decrease of IGF-I in the first
trimester of pregnancy may be related to decreased pro-
duction or increased turnover rather than to a marked
decrease in pituitary GH secretion [7]. Also, high estradiol
levels interfere with the hepatic production of IGF-I during
the first part of pregnancy. This effect, however, seems to be
overridden by the progressive secretion of placental GH [7].
This predominant effect of placental GH on maternal IGF-I
in late pregnancy is also nicely illustrated by the marked
drop of IGF-I 2 days after delivery [7].
In normal pregnancy, the physiological increase in estro-
gen and progesterone has known consequences for the sen-
sitivity of the liver for GH, as was recently described and
confirmed by Persechini et al. [2]. While this phenomenon is
present in normal pregnancies, it’s also present in acromegaly.
Administration of high doses of estrogens to patients with
acromegaly has been shown already more than 50 years ago to
improve symptomatology of acromegaly and glucose toler-
ance [8]. Selective estrogen receptor modulators (SERMs)
mimic the effects of estrogen in bone, liver and the cardio-
vascular system, but act as anti-estrogens in endometrial and
breast tissue [9]. Balili and Barkan [9] evaluated hormonal
effects of the SERM tamoxifen in 15 male acromegaly
patients with active disease and 2 post-menopausal women,
also with biochemically-active acromegaly despite the fact
that other modalities were ineffective in normalizing their
IGF-1 levels. They observed that tamoxifen did not affect
basal GH secretion, but it decreased circulating IGF-I in 14
patients (82 %) and normalized plasma IGF-I in 8 patients
(47 %) [9].
During the second half of normal pregnancy, the human
placenta secretes its specific GH variant (placental GH; pGH)
in increasing amounts up to delivery. During the same period,
pituitary GH secretion is progressively suppressed [3]. Note-
worthy is that the high homology of GH with pGH frequently
results in falsely high GH levels in competitive immunoassays
during pregnancy [10]. However, in immunometric assays,
falsely high or low GH levels can result from GH-like mole-
cules binding to both or only one monoclonal antibody [10].
Dias et al. [10] evaluated potential negative interference of
pregnancy serum in their GH-IFMA assay. Addition of
pregnancy serum to ‘acromegaly’ serum resulted in a marked
decrease in GH, but addition of pGH did not change GH
measurements [10]. Therefore, GH measurements in preg-
nancy by immunometric assays must be made after exclusion
of pregnancy serum interference by dilutional tests [10].
Ringholm and coworkers evaluated whether levels of
pGH and IGF-I are associated with development of large
for gestational age (LGA) infants in pregnant women with
type-1 diabetes [11]. Women delivering LGA infants had
lower placental GH levels in early pregnancy [11].
Apparently, growth factors and maternal weight gain in
early pregnancy may be important for healthy fetal growth.
Therefore, the lack of fetal abnormalities in children born
out of acromegaly mothers shows that, apparently, the
normal physiological drivers seem to control the autono-
mous GH secretion by the somatotropinoma.
The human placental lactogen (hPL) gene family consists
of two GH and three PL genes [12]. pGH expressed by the
placenta, becomes the predominant GH in the mother. hPL,
which is the product of the hPL-A and hPL-B genes, is
secreted into both the maternal and fetal circulations after the
sixth week of pregnancy [12]. pGH and hPL act in concert in
the mother to stimulate IGF-I and modulate intermediary
metabolism, resulting in an increase in the availability of
glucose and amino acids to the fetus. hPL acts via lactogenic
receptors and possibly a unique PL receptor in the fetus. This
modulates embryonic development, regulate intermediary
metabolism and stimulate the production of IGFs, but also
pulmonary surfactant [12].
The conceptual changes during pregnancy in normal
subjects and women with acromegaly are shown in Fig. 1.
What happens if medical treatment is stopped?
The reasons behind the apparent lack of biochemical
escape in pregnant acromegaly patients when medical
treatment is stopped were already addressed by Beckers
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et al. [4]. They described 2 young women who remained
acromegalic despite transsphenoidal removal of their
pituitary adenomas. Increased basal levels of GH and IGF-
1 as well as paradoxical GH release after TRH injection
were noted [4]. Both women became pregnant and deliv-
ered term babies without any complication. In both
patients, pituitary GH remained elevated during the entire
pregnancy, contrary to the situation in normal women.
Tissue placental GH concentrations were within the range
of levels in normal placentas. An increase in serum IGF-1
in late pregnancy was also similar to that observed in
normal pregnancy. This confirms that increased IGF-I
levels are not pituitary GH dependent in late pregnancy.
Apparently, adenomatous somatotrophs lack an IGF-I-de-
pendent feedback regulation present in normal soma-
totrophs [4].
Most acromegaly patients who become pregnant while
on medical therapy in fact represent patients in which the
fetus encounters the compound that is used by the mother
for at least the first 6 weeks or so. To our knowledge no
controlled data exist of women who preconceptionally
stopped medication to prevent exposure of the fetus. Also
there is a complete lack of data on safety in those who start
taking medication to control acromegaly, as the indication
for this is extremely rare.
Because of the overlap between the normal gestational
acromegaly and pregnancy in acromegaly, the distinction
between the two more or less disappears. In a recent
prospective study in 10 pregnancies in 8 acromegaly
patients, in whom medication for acromegaly was stopped
immediately following confirmation of pregnancy, Dias
et al. [13] describe that no tumor growth was observed.
Nine deliveries were at term and one at 35 weeks
(preeclampsia). No fetal abnormalities were observed.
Mean IGF-1 levels before and during pregnancy were
similar, but increased significantly during puerperium [13].
As IGF-1 in normal pregnancies is already increased after
midgestation, the prevalence of controlled IGF-1 in those
10 pregnancies rose significantly from 2/10 (\20 weeks) to
9/10 ([30 weeks) [13].
But even in the case that GH and IGF-1 don’t become
normal during pregnancy in at least a subsection of sub-
jects, the fetus is protected for this as GH and IGF-1 don’t
seem to cross the placenta [14].
Tumor size is another important issue in acromegaly.
Stopping medication might have clinical consequences for
the patient when tumor size increases. Only very few
patients with tumors that secrete GH have been reported to
have had enlargement of their tumors during pregnancy
[15, 16]. Therefore, in a review by Molitch, he concludes
that surgery or medical therapy for somatotropinomas and
for clinically nonfunctioning adenomas is almost never
indicated during pregnancy [17].
In a recent review Cheng et al. [18] also reported that
most patients with acromegaly during pregnancy do not
have an increase in tumor size, and metabolic complica-
tions are uncommon.
Caron et al. [19] reported on a retrospective multicenter
study of 59 pregnancies in 46 women with acromegaly that
pregnancy in women with active or uncontrolled acrome-
galy may be associated with an increased risk of as already
mentioned not only gestational diabetes but also gravid
hypertension. The IGF-axis may be also implicated in
glucose homeostasis, but its longitudinal profile across
gestation in relation to the development of gestational
diabetes (GDM) is largely unknown [20]. Zhu et al.
prospectively investigated IGF-axis biomarkers in early-to-
mid pregnancy in relation to subsequent GDM risk in a
case–control study of 107 GDM cases and 214 non-GDM
controls. They showed that the IGF-axis, IGFBP-2 in
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particular, may be implicated in the pathogenesis of GDM
with significant associations and incremental predictive
value detected as early as the end of the first trimester,
approximately 10–18 weeks earlier before GDM is typi-
cally screened for. The risk of GDM seems to be increased
in acromegaly as GDM was diagnosed in four of the 59
pregnancies (6.8 %) in the series reported by Caron et al.
[19]. Three of these four women did not have diabetes
mellitus before pregnancy, whereas acromegaly was diag-
nosed during pregnancy in the fourth woman, and the
existence of diabetes mellitus before pregnancy could not
be ascertained [19].
Cheng et al. [21] report in 13 newly described preg-
nancies along with systematic review of an additional
34 cases that pregnancy in treated acromegalic women
can proceed without significant complications or
teratogenicity.
Safety aspects of using dopamine agonists
during pregnancy
Cheng et al. [18] report to have found that dopamine
agonists, somatostatin analogues, and pegvisomant have
been reported to be safe during pregnancy.
Most data on safety of the use of dopamine agonists
during 61 pregnancies in 50 women treated with caber-
goline were obtained by Ricci et al. from women with
prolactinomas, however [22]. Short-term treatment with
bromocriptine has not been found to cause any increase
in spontaneous abortions, ectopic pregnancies, tro-
phoblastic disease, multiple pregnancies, or congenital
malformations [23–25]. Yap et al. [26] reported a case of
acromegaly diagnosed in the second trimester of preg-
nancy, in which bromocriptine corrected visual field
defects and suppressed prolactin secretion but did not
reduce fasting growth hormone levels. In 1976 already,
Aono et al. [27] reported a case of an acromegalic
patient with galactorrhea-amenorrhea who conceived
following long-term bromocriptine therapy. They showed
that bromocriptine can restore ovulatory function not
only to the patient with a hypothalamic disorder but also
to acromegalic patients.
Experience with the use of cabergoline in pregnancy is
limited [28]. Ricci et al. [28] collected information on 61
pregnancies in 50 women treated with cabergoline. These
pregnancies resulted in 12 (19.7 %) early terminations (five
induced abortions, six spontaneous abortions, one hyda-
tidiform mole) and 49 (80.3 %) live births. Their data in
combination with previous reports can more or less exclude
a major congenital malformation risk [10 % associated
with pregnancy exposure to cabergoline [28–30].
Safety aspects of using somatostatin analogs
during pregnancy
Maffei et al. [31] reported a case study on the effects of
octreotide, a somatostatin receptor ligand (SRL) on uterine
artery blood flow, which they addressed as acute, rever-
sible, and clinically irrelevant hemodynamic changes in the
maternal-fetal barrier. A certain degree of mother-to-fetus
transplacental passage of at least octreotide seems to occur
by passive diffusion [31, 32]. Fassnacht et al. reported a
24-year-old woman with active acromegaly despite pitu-
itary surgery and irradiation who received continuous
octreotide LAR treatment for the control of GH excess
throughout her pregnancy. The patient delivered a healthy
girl following an uneventful pregnancy [33]. Takano et al.
reported a 35-year-old woman with active acromegaly who
also received continuous octreotide LAR treatment for the
control of GH excess until discovery of her pregnancy. The
patient delivered a healthy boy following an uneventful
pregnancy after discontinuing octreotide LAR as soon as
possible at the early phase of pregnancy [34].
Neal [35] reported a successful pregnancy in a 43-year-
old woman with acromegaly and treatment during preg-
nancy with octreotide. This patient decided to continue
octreotide therapy because of the relatively large size of the
tumor and severe headaches when use of the medication
was discontinued. Interestingly, GH and IGF-I levels
remained normal throughout pregnancy, and a normal full-
term infant was born. In their review they also reported
about 6 other women, who used octreotide during the first
trimester of pregnancy in seven other women with acro-
megaly (and throughout pregnancy in one) [35]. No
adverse effects on the fetus were observed [35]. Also,
lanreotide was also used in one patient briefly during the
first trimester without adverse consequences [35].
Caron et al. reported four women who gave birth to a
small-for-gestational-age infant without gross malforma-
tions while receiving a somatostatin analog alone (n = 2)
or combined with a dopamine agonist (n = 2) during
\2 months of pregnancy [11]. Short-acting octreotide
induce an acute, reversible, and clinically irrelevant
hemodynamic changes in the uterine artery [31]. Whether
or not these effects of octreotide are responsible for the
microsomia that Caron et al. observed is unclear.
Safety aspects of using pegvisomant
during pregnancy
Van der Lely et al. [36] summarized all available data on
pregnancy outcome of 35 casus of acromegaly patients
exposed to pegvisomant (PEGV) during pregnancy as
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present in the Pfizer’s Global Safety Database up to March
2014.
Although the number of reported pregnancies with
exposure to PEGV was very small, the presented data
reflect the largest series of data available to date and do not
suggest adverse consequences of PEGV on pregnancy
outcome [36]. Nevertheless, they stressed out that PEGV
should not be used during pregnancy unless absolutely
necessary. Riddle Brian et al. already reported a case of a
26-year-old female with acromegaly who had failed sur-
gical and subsequent medical therapy but whose disease
was well controlled on PEGV [37]. The patient conceived
and was continued on PEGV throughout pregnancy. They
also collected both maternal and cord blood samples at
parturition, and later analyzed her breast milk.
They observed that maternal IGF-I was well controlled
during gestation and fetal GH and IGF-1 were within the
normal range. Maternal PEGV levels were consistent with
a 25 mg daily dosage. Fetal- and breast milk PEGV levels
appeared to be minimal and near the range that can be
detected in untreated acromegalic patients [37].
Conclusions
Acromegaly is characterized by changes in concentrations
and actions of GH, IGF-1 and insulin. All these hormones
play an essential role in pregnancy as well. In principle, the
placenta takes over the control over maternal GH and IGF-
1 secretion, not only in normal physiology but also to a
certain extend in acromegaly.
During normal pregnancy, placental GH rises expo-
nentially until 37 weeks. Meanwhile, pituitary GH gradu-
ally drops to near-undetectable levels. While there might
be a modest reduction in circulating IGF-I in early preg-
nancy, IGF-I increases two- to three-fold in the second
half, again with a peak at around 37 weeks.
The question is whether or not patients with acromegaly
should be treated for the disease during pregnancy anyway.
The consensus is, however, that there is no indication to
use medication to control GH hypersecretion or tumor size
in acromegaly patients during pregnancy.
When for whatever reason medication for the high GH
levels or actions is continued during pregnancy, both
dopamine agonists, somatostatin analogs and growth hor-
mone receptor antagonists have been used and the available
data suggest that there are no adverse consequences on
mother or fetus to date, although again it is generally
advised to stop any medical intervention during pregnancy
as stopping until postpartum reactivation of the disease
activity has been proven to be safe for mother and child.
Also, more data on the safety of these compounds are
lacking.
This results in the following recommendations:
• When practical feasible, women could stop medication
before conception, although data to support a positive
effect of this are lacking. This also accounts for male
acromegaly fathers to be.
• When pregnancy is confirmed, medical treatment can
be stopped in almost every patient, as biochemical
escape is very unlikely, which also accounts for tumor
size.
• When need for medical intervention is indicated to
control e.g. tumor-size or severe headaches, all avail-
able medical treatment modalities seem to be safe
enough, although large series are lacking.
• In order to detect increases in tumor-size early enough,
visual field assessments are indicated every trimester,
but only in those subjects with large tumors that extend
to the optic chiasm only. When visual fields become
abnormal, this must be followed by an MRI of the sellar
region.
• When (although very uncommon) an unacceptable in-
crease tumor size is detected, transsphenoidal surgery
might be indicated.
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